In HS, a study by Straalen et al. identified TNF-α, IL-1β, SFRP4+, and CXCL13+ as relevant therapeutic targets for HS patients through spatial sequencing and complement analysis5. Here, SFRP4 is linked to histiocytic sarcoma.